Pliant Therapeutics Earnings Reports

Pliant Therapeutics reported a net loss of $22.9 million for the first quarter of 2021, compared to a net income of $11.0 million for the prior-year quarter. Research and development expenses increased to $18.5 million, and general and administrative expenses rose to $6.6 million. As of March 31, 2021, the company had $264.1 million in cash, cash equivalents, and short-term investments.

Pliant Therapeutics reported a net loss of $19.0 million for the fourth quarter of 2020, compared to a net income of $42.2 million for the prior-year quarter, due to a decrease in related party revenue. Research and development expenses increased to $17.9 million, and general and administrative expenses were $5.6 million. The company had cash, cash equivalents, and short-term investments of $276.9 million as of December 31, 2020.

Pliant Therapeutics reported related party revenue of $4.8 million for the third quarter of 2020, compared to none for the prior-year quarter. Research and development expenses were $16.9 million, and net loss was $16.5 million. The company had cash, cash equivalents, and short-term investments of $294.0 million as of September 30, 2020.